Ingram Douglas S's Form 4 filing
Sarepta Therapeutics, Inc. (SRPT) · filed Nov 6, 2023
- Accession no.
- 0001209191-23-054441
- Filed
- Nov 6, 2023
- Trade date
- Nov 3, 2023
- Filing delay
- 3 days
- Rule 10b5-1 plan
- Not checked
This filing lists 4 non-derivative transactions and 0 derivative transactions. Open-market purchases total $2.00M. It was filed 3 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Ingram Douglas SCIK 0001190644 | Director, Officer (President & CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 3, 2023 | Common Stock | PPurchaseAcquired | +10,081 | $78.57 | +$792,064.17 | 375,163 | Direct | |
| Nov 3, 2023 | Common Stock | PPurchaseAcquired | +11,060 | $79.70 | +$881,482 | 386,223 | Direct | |
| Nov 3, 2023 | Common Stock | PPurchaseAcquired | +3,884 | $80.33 | +$312,001.72 | 390,107 | Direct | |
| Nov 3, 2023 | Common Stock | PPurchaseAcquired | +200 | $81.26 | +$16,252 | 390,307 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.